A Republican bill with 1 Democratic cosponsor · See the cosponsor
Last activity — Read twice and referred to the Committee on Finance.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill is called the Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act or the PROTECT for Rare Act. It aims to update coverage rules for certain drugs used to treat rare diseases or conditions affecting 200,000 or fewer people in the United States. The legislation covers programs under Medicare, Medicaid, and private health insurance. Under the bill, qualifying uses for rare disease drugs must be supported by medical literature, clinical guidelines, or medical experts. It also sets up an expedited review process for private health insurance coverage denials regarding these specific drugs. The changes outlined in the bill are scheduled to take effect starting on January 1, 2027.
Yes· 3 of 14
- Scored +7
Would people with disabilities be better off under this?
Provides substantial benefits to individuals with severe or rare medical conditions and disabilities by securing treatment access.
- Scored +7
Does this make health care easier to get in general?
Improves healthcare access by clarifying and expanding coverage pathways for specialized rare disease medications across Medicare, Medicaid, and private insurance.
- Scored +6
Would people over 65 be better off under this?
Directly benefits seniors by updating Medicare definitions to explicitly cover qualifying rare disease treatments.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 2(a) updates Medicare rules to explicitly include coverage for certain drugs used to treat rare diseases or conditions affecting 200,000 or fewer individuals, provided the use is supported by peer-reviewed medical literature or clinical guidelines. This is positive because it helps Medicare patients access necessary treatments for rare conditions.
-
Section 2(b) updates the definition of medically accepted indications under Medicaid for drugs treating rare diseases or conditions affecting 200,000 or fewer individuals based on peer-reviewed literature, clinical guidelines, or medical society experts. This helps lower-income individuals on Medicaid gain clearer coverage pathways for specialized rare disease medications.
-
Section 2(c) requires group health plans and health insurance issuers to provide an expedited appeal process for denied coverage of drugs used to treat rare diseases or conditions affecting 200,000 or fewer individuals. This benefits patients with private insurance by giving them a faster way to fight a coverage denial for their rare disease treatments.
Potential Negative Impacts for People
- The provided text does not contain explicit details regarding potential negative consequences or burdens for individuals or groups of people.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would people with disabilities be better off under this? — Provides substantial benefits to individuals with severe or rare medical conditions and disabilities by securing treatment access. Would households on low incomes be better off under this? — Helps lower-income individuals on Medicaid gain clearer coverage pathways for specialized rare disease medications. Would retired people be better off under this? — Positively impacts retirees relying on Medicare coverage for specialized rare disease therapeutics. Would people over 65 be better off under this? — Directly benefits seniors by updating Medicare definitions to explicitly cover qualifying rare disease treatments. Would children be better off under this? — Helps children suffering from rare pediatric diseases or conditions gain reliable drug coverage. Would people in middle age be better off under this? — Supports middle-aged individuals dealing with rare diseases by clarifying Medicare and insurance requirements. Would middle-income households be better off under this? — Aids middle-class households facing rare diseases by ensuring clearer insurance coverage and expedited appeals. Would people in their twenties and thirties be better off under this? — Assists young adults managing rare medical conditions through improved coverage rules.
- Healthcare
- Does this make health care easier to get in general? — Improves healthcare access by clarifying and expanding coverage pathways for specialized rare disease medications across Medicare, Medicaid, and private insurance. Does this put more money into Medicaid, the health coverage for people on low incomes? — Expands medically accepted indications under Medicaid for drugs used to treat rare diseases supported by literature and clinical guidelines. Does this put more money into Medicare, the health coverage for people over 65? — Updates Medicare rules to explicitly include coverage for qualifying rare disease treatments based on peer-reviewed literature.
- Governance And Ideology
- Does this protect the right to fair treatment by the courts? — Enhances due process for patients and physicians by creating formal expedited review processes for insurance coverage denials. Does this give the federal government more power? — Increases federal oversight requirements on group health plans and insurance issuers regarding rare disease coverage appeals.
- Economy And Finance
- Does this give people more protection from unfair business practices? — Improves consumer protection by establishing expedited appeal processes for rare disease drug coverage denials.
- 12/17/2025
- Read twice and referred to the Committee on Finance.
- 1 Cosponsor added.
- Introduced in Senate
Martin HeinrichDemocrat · New Mexico